Back to Results
Treatment for Children with Newly Diagnosed Standard Risk Medulloblastoma
Brain Tumor - Treatment for Children with Newly Diagnosed Standard Risk Medulloblastoma
Brain Tumors (Pediatric)
||Michael J. Kelly, MD
This study is for people who have a type of cancer called medulloblastoma, which is a kind of childhood brain tumor. This study will look at what will happen if a smaller amount of radiation therapy is given to the brain and spinal cord of children with medulloblastoma. Some patients on this study will be given a standard dose of radiation and others will receive a reduced dose.In addition this study will look at what will happen if the volume of radiation that is given during the “boost dose” of radiation is reduced. A “boost dose” is extra radiation delivered to the tumor area. Some patients on this study will be given a standard-volume boost, which means that the radiation is targeted at the entire posterior fossa. Other patients will be given a smaller volume boost which means that they will be given radiation targeted more directly to the tumor bed.
- Diagnosis of Average Risk Medulloblastoma, less than 1.5 cm² tumor remaining after surgery
- Adequate kidney, liver, and bone marrow function
- Presence of Metastatic disease
- Pregnancy or breast-feeding
- Previous radiotherapy or chemotherapy other than corticosteroids
This is a Phase III randomized study for patients with newly diagnosed standard risk medulloblastoma. Subjects will receive chemotherapy and radiation. Subjects ages 3 – 7 will be randomized to standard versus reduced dose Craniospinal Radiation Therapy. After receiving craniospinal radiation, all patients are then randomized to receive standard radiation to the entire posterior fossa versus a reduced dose of radiation to only the tumor bed. All patients then receive maintenance chemotherapy.
Are you interested in learning more about this clinical trial?
Send us a message and we'll get back to you with more information.